Drugmakers race to find a place in the next wave of obesity drugs

Drugmakers are only months into introducing GLP-1 pills and navigating huge changes in how patients pay for weight-loss drugs. Even so, they're already outlining their visions for the future of obesity drugs. At the American Diabetes Association's Scientific Sessions in New Orleans last week, drugmakers pitched doctors and investors on the idea of new shots and pills, drugs that can be taken less frequently, and new treatments beyond GLP-1s that could come with fewer side effects. The attendees debated where all these new treatments might fit in, especially with Eli Lilly currently dominating the market for shots and impressing attendees with data from its experimental triple-acting drug retatrutide that produced the most weight loss seen yet.

…

Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Top.